ea0026p583 | Clinical case reports | ECE2011
Zuhur Sayid Shafi
, Musluman Ahmet Murat
, Tanik Canan
, Karaman Ozcan
, Ozturk Feyza Yener
, Ozkayalar Hanife
, Altuntas Yuksel
Background: Currently, no effective medical treatment exists for recurrent and aggressive craniopharyngiomas that are resistant to conventional therapies, including repeat surgeries and adjuvant radiotherapy (RT). Temozolomide is an alkylating chemotherapeutic agent and is used routinely in the management of high grade gliomas. The response to temozolomide is suggested to be dependent on the tumoral expression of O-6 methylguanine DNA methyltransferase (MGMT). Evidence ...